JP2002525280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002525280A5 JP2002525280A5 JP2000571048A JP2000571048A JP2002525280A5 JP 2002525280 A5 JP2002525280 A5 JP 2002525280A5 JP 2000571048 A JP2000571048 A JP 2000571048A JP 2000571048 A JP2000571048 A JP 2000571048A JP 2002525280 A5 JP2002525280 A5 JP 2002525280A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- hydrogen
- disorder
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 23
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000011282 treatment Methods 0.000 description 5
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 3
- -1 arylsulfoxyl Chemical group 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DRLGTCNDEBEPQP-UHFFFAOYSA-N 1-(5,6-difluoro-3-methylindazol-1-yl)propan-2-amine Chemical compound FC1=C(F)C=C2N(CC(N)C)N=C(C)C2=C1 DRLGTCNDEBEPQP-UHFFFAOYSA-N 0.000 description 1
- QGDUUJDJXSDKCP-UHFFFAOYSA-N 1-(6-bromo-3-ethylindazol-1-yl)propan-2-amine Chemical compound BrC1=CC=C2C(CC)=NN(CC(C)N)C2=C1 QGDUUJDJXSDKCP-UHFFFAOYSA-N 0.000 description 1
- PKGIAAHUVWWFPM-UHFFFAOYSA-N 1-(6-chloro-5-fluoro-3-methylindazol-1-yl)propan-2-amine Chemical compound FC1=C(Cl)C=C2N(CC(N)C)N=C(C)C2=C1 PKGIAAHUVWWFPM-UHFFFAOYSA-N 0.000 description 1
- WMYZYDUOEKWORM-UHFFFAOYSA-N 1-(6-methoxy-3-methylindazol-1-yl)propan-2-amine Chemical compound COC1=CC=C2C(C)=NN(CC(C)N)C2=C1 WMYZYDUOEKWORM-UHFFFAOYSA-N 0.000 description 1
- OCJCKHPFQNWROT-UHFFFAOYSA-N 1-[3-ethyl-6-(trifluoromethyl)indazol-1-yl]propan-2-amine Chemical compound FC(F)(F)C1=CC=C2C(CC)=NN(CC(C)N)C2=C1 OCJCKHPFQNWROT-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- 125000005202 dialkylaminocarbonyloxy group Chemical group 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 201000000484 premenstrual tension Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9819032.5 | 1998-09-01 | ||
| GBGB9819032.5A GB9819032D0 (en) | 1998-09-01 | 1998-09-01 | Chemical compounds IV |
| PCT/GB1999/002875 WO2000012481A2 (en) | 1998-09-01 | 1999-09-01 | Indazole derivatives with 5-ht2 receptor activity________________ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002525280A JP2002525280A (ja) | 2002-08-13 |
| JP2002525280A5 true JP2002525280A5 (enExample) | 2006-10-26 |
Family
ID=10838164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000571048A Pending JP2002525280A (ja) | 1998-09-01 | 1999-09-01 | ５−ｈｔ２レセプター活性を有するインダゾール誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6552062B1 (enExample) |
| EP (1) | EP1129078B1 (enExample) |
| JP (1) | JP2002525280A (enExample) |
| AT (1) | ATE320419T1 (enExample) |
| AU (1) | AU5636799A (enExample) |
| CA (1) | CA2341612A1 (enExample) |
| DE (1) | DE69930397T2 (enExample) |
| ES (1) | ES2260931T3 (enExample) |
| GB (1) | GB9819032D0 (enExample) |
| WO (1) | WO2000012481A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9820767D0 (en) * | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
| GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
| US6956036B1 (en) * | 2000-03-17 | 2005-10-18 | Alcon, Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
| AU2001216072A1 (en) * | 2000-03-17 | 2001-10-03 | Alcon, Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| DE60139021D1 (de) | 2000-11-20 | 2009-07-30 | Biovitrum Ab Publ | Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors |
| JP2005506280A (ja) | 2000-12-20 | 2005-03-03 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | アリールおよびアミノアリール置換セロトニン受容体アゴニストおよびアンタゴニストリガンド |
| AU2002360819A1 (en) * | 2001-12-28 | 2003-07-24 | Bayer Corporation | Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| EP1513831B1 (en) | 2002-06-19 | 2010-01-06 | Biovitrum AB (publ) | Novel compounds, their use and preparation |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| JPWO2011071136A1 (ja) | 2009-12-11 | 2013-04-22 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0232059A (ja) * | 1988-07-18 | 1990-02-01 | Kyowa Hakko Kogyo Co Ltd | インダゾール誘導体 |
| US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
| TW270114B (enExample) * | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
| JPH08225535A (ja) * | 1994-11-15 | 1996-09-03 | Dai Ichi Seiyaku Co Ltd | インダゾール誘導体 |
| AU5343298A (en) * | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
-
1998
- 1998-09-01 GB GBGB9819032.5A patent/GB9819032D0/en not_active Ceased
-
1999
- 1999-09-01 DE DE69930397T patent/DE69930397T2/de not_active Expired - Fee Related
- 1999-09-01 JP JP2000571048A patent/JP2002525280A/ja active Pending
- 1999-09-01 EP EP99943082A patent/EP1129078B1/en not_active Expired - Lifetime
- 1999-09-01 WO PCT/GB1999/002875 patent/WO2000012481A2/en not_active Ceased
- 1999-09-01 US US09/763,886 patent/US6552062B1/en not_active Expired - Fee Related
- 1999-09-01 AT AT99943082T patent/ATE320419T1/de not_active IP Right Cessation
- 1999-09-01 CA CA002341612A patent/CA2341612A1/en not_active Abandoned
- 1999-09-01 AU AU56367/99A patent/AU5636799A/en not_active Abandoned
- 1999-09-01 ES ES99943082T patent/ES2260931T3/es not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002523491A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2002525280A5 (enExample) | ||
| JP2002523506A5 (enExample) | ||
| JP2003507367A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2007516941A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| JP2003507366A5 (enExample) | ||
| JP2004532823A5 (enExample) | ||
| JP2004505085A5 (enExample) | ||
| JP2004527467A5 (enExample) | ||
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| JP2002535408A5 (enExample) | ||
| RU2018130727A (ru) | Органические соединения | |
| RU2001108570A (ru) | Пирролоиндолы, пиридиноиндолы и азепиноиндолы в качестве агонистов 5-нт2с | |
| CA2422698A1 (en) | Indoline derivatives and their use as 5-ht2 receptor ligands | |
| JP2007508360A5 (enExample) | ||
| CA2702482A1 (en) | Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| JP2014526435A5 (enExample) | ||
| JP2005526723A5 (enExample) | ||
| RU95113149A (ru) | Трициклические производные пиразола | |
| RU2006116885A (ru) | Производные n-фенил(пиперидин-2-ил)метил-бензамида, способ получения указанных соединений и их применение в терапии | |
| HRP20090640T1 (hr) | Kristalinični oblici (r)-8-kloro-1-metil-2,3,4,5-tetrahidro-1h-3-benzazepin hidroklorida | |
| JP2004519438A5 (enExample) |